Sharemaestro company-news research for NeuroScientific Biopharmaceuticals Limited (NSB), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
ASX
Australia
Provisional evidence
Company news sentiment
Latest NSB news and sentiment
NeuroScientific Biopharmaceuticals Limited
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
1 company-specific story are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone57/100
→
Published 30-day score50/100
Latest source headline
NeuroScientific Biopharmaceuticals (ASX:NSB) Rises 5% as StemSmart Program Progresses
Kalkine · 05 Oct 2026 12:45
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
1 current stories are mapped specifically to NSB.
What limits the score
Only 1 publisher currently contribute to the measured read.
Confidence is 16/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news1 company stories
N/A/100
Story agreementrequires at least 2 stories
News history
Daily score and story count over 30 days
12 Sep27 Sep11 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.009 after freshness weightingSource breadth20
1 independent publishersCompany relevance100
share tied directly to this companyFreshness34
recency-weighted evidenceAgreement0
requires at least 2 storiesPublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks20 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650AUD 0.058+0.0%
02 Oct 202650AUD 0.058-6.5%
25 Sep 202650AUD 0.062+1.6%
18 Sep 202650AUD 0.061-1.6%
11 Sep 202650AUD 0.062+1.6%
04 Sep 202650AUD 0.061-1.6%
28 Aug 202650AUD 0.062-4.6%
21 Aug 202650AUD 0.065+12.1%
Provisional evidence
News subjects
What is shaping the score
Market update571 stories · 100%
Source mix
Where the evidence comes from
Kalkine571 stories · 100%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
26 May50 neutral11 Oct 17:45
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 17:45 | 50 | +0 | 16/100 (-11) | 1 (-1) | Provisional |
| 05 Oct 23:59 | 50 | +0 | 27/100 (+13) | 2 (-3) | Provisional |
| 08 Sep 23:59 | 50 | +0 | 14/100 (-1) | 5 (+1) | Provisional |
| 04 Sep 23:59 | 50 | +0 | 15/100 (-12) | 4 (-1) | Provisional |
| 25 Aug 23:59 | 50 | +0 | 27/100 (+13) | 5 (+1) | Provisional |
| 13 Aug 23:59 | 50 | +0 | 14/100 (-3) | 4 (0) | Provisional |
| 04 Aug 23:59 | 50 | +0 | 17/100 (-10) | 4 (+1) | Provisional |
| 31 Jul 23:59 | 50 | +0 | 27/100 (+27) | 3 (-2) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 1 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Market update1 story
0.0%100.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
57/100 tone
100% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 05 Oct 2026 12:45
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 100% of directional evidence · 6.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Earlier company news
NSB news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
08Sep 2026
Article detailsHistorical record
- Published
- 8 Sep 2026 07:20
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
04Sep 2026
ArchivedNeutral tone
NeuroScientific Biopharmaceuticals Changes External Auditor Ahead of October AGM
Article detailsHistorical record
- Published
- 4 Sep 2026 05:13
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
27Aug 2026
ArchivedNegative tone
NeuroScientific Biopharmaceuticals Widens Annual Loss Despite Surge in Income
Article detailsHistorical record
- Published
- 27 Aug 2026 18:33
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
25Aug 2026
ArchivedNegative tone
NeuroScientific Biopharmaceuticals Widens Annual Loss Despite Surge in Income
Article detailsHistorical record
- Published
- 25 Aug 2026 09:12
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
13Aug 2026
Article detailsHistorical record
- Published
- 13 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
13Aug 2026
Article detailsHistorical record
- Published
- 13 Aug 2026 02:34
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
04Aug 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Why NeuroScientific Biopharmaceuticals (ASX:NSB) Shares are Trading Higher on Tuesday?
Article detailsHistorical record
- Published
- 4 Aug 2026 10:55
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
31Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Neuroscientific Biopharmaceuticals (ASX:NSB) Surges as Neurological Drug Research Returns to Focus
Article detailsHistorical record
- Published
- 31 Jul 2026 14:54
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
11Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Neuroscientific Biopharmaceuticals Options Expire Unexercised, Trimming Equity Overhang
Article detailsHistorical record
- Published
- 11 Jul 2026 16:15
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
10Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Is NeuroScientific Biopharmaceuticals (ASX: NSB) Still Worth Watching After Today's Drop?
Article detailsHistorical record
- Published
- 10 Jul 2026 08:20
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Price to earnings forward of Neuroscientific Biopharmaceuticals Ltd. – ASX:NSB
Article detailsHistorical record
- Published
- 1 Jul 2026 03:25
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
25Jun 2026
ArchivedLegacy · tone unscored
Legacy source lookup
NeuroScientific Biopharmaceuticals Directors and Advisers Voluntarily Re-Escrow 77.9 Million Shares Ahead of Phase 2 Clinical Trial Commencement
Article detailsHistorical record
- Published
- 25 Jun 2026 23:27
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
26May 2026
Article detailsHistorical record
- Published
- 26 May 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
26May 2026
Article detailsHistorical record
- Published
- 26 May 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Aug 2025
Article detailsHistorical record
- Published
- 1 Aug 2025 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
27Sep 2019
ArchivedNeutral tone
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)
Article detailsHistorical record
- Published
- 27 Sep 2019 05:05
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to NSB, but the headline and available text are not mainly about NeuroScientific Biopharmaceuticals Limited. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of NSB sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.